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Our patient is a 64-year-old Chinese woman with a history 
of asthma with previous prednisolone usage, diabetes melli-
tus, and breast cancer—for which left simple mastectomy and 
axillary clearance was performed. Her menopause had been at 
54 years and she had been on alendronate for 1 year for osteo-
penia, diagnosed by bone mineral density scan.
She was referred to our department 1 month after her mas-
tectomy for bilateral thigh pain that had lasted 2 weeks, to 
exclude metastases before commencing chemotherapy. The 
thighs were tender bilaterally. Plain radiographs of her femurs 
showed lateral cortex thickening bilaterally with a stress frac-
ture of her right femoral shaft (Figure 1). She had increased 
uptake at the lower one-third of her right femur and the proxi-
mal one-third of her left femur on Tc-99m bone scan. 
In  view  of  the  above  findings,  she  was  advised  to  stop 
alendronate and was wheelchair-mobilized for 6 weeks. The 
option of intramedullary nailing for the right femur stress frac-
ture and prophylactic nailing of the left femur was discussed 
with the patient, but on follow-up, there was radiographic evi-
dence of fracture healing (Figure 2).
Bone mineral density scan at 3 years since stopping alendro-
nate was normal. Repeat Tc-99m bone scan showed reduced 
Figure 1. Right (A) and left (C) femur showing lateral cortex thickening. Right 
femur also showing an undisplaced fracture (B; arrow).
uptake of tracer at the right femur compared to the 
previous bone scan, consistent with a healing frac-
ture. Apart from occasional bilateral thigh pain, our 
patient  was  otherwise  well.  She  was  converted  to 
letrazole with ibandronic acid by her oncologist at 
the 5-year follow-up. Once again, she complained of 
bilateral aching thigh pain on walking and standing, 
with difficulty climbing stairs. Plain radiographs of 
her femurs did not reveal any new fractures.
She was still ambulating until 7 months after start-
ing ibandronate, when she fell in the toilet after a 
sudden onset of severe bilateral thigh pain; she was 
brought to the emergency department with bilateral 
thigh pain and deformity. Plain radiographs of both 
her femurs showed bilateral shaft fractures (Figure 
3). Blood biochemistry showed a normal serum alka-
line phosphatase level, 41 U/L (32–103), and normal 
total serum calcium, 2.11 mmol/L (2.10–2.60). Her 
serum Ca 15-3 level, a tumor marker for breast carci-
noma, was not elevated either. 
Plate fixation of both femoral shafts was performed 
in a single operation instead of intramedullary nail-
ing with a risk of fat embolism, in view of her his-
tory of asthma with baseline hypoxemia (Figure 4). 
She  was  wheelchair-mobilized  again  after  surgery 
and histology from both fracture sites showed frac-
ture hematoma with no evidence of malignancy. The 
fractures healed uneventfully.
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Discussion 
The calculated incidence of bisphosphonate-associated femo-
ral diaphyseal fractures has been estimated to be 1 in 1,000 
patients per year (Schilcher and Aspenberg 2009). These frac-
tures have been described in patients receiving alendronate 
for 5–7 years (Kwek et al. 2008, Lenart et al. 2009). Authors 
have recommended plain radiographs of symptomatic patients 
to check for lateral femoral cortex thickening and “beaking” 
with a short oblique or transverse fracture line such as in our 
patient (Kwek et al. 2008, Lenart et al. 2009). Our patient 
had received alendronate for only 2 years, yet had evidence 
on plain radiographs of the aforementioned changes related to 
its use and with its associated prodromal symptoms. Similar 
fracture patterns have been reported in patients who were not 
on bisphophonate therapy (Tan et al. 2010). 
The described half-life of alendronate is 10 years and its 
continued effect after cessation of therapy is why a “drug holi-
day” works in selected patients who respond to therapy with 
normal bone mineral density scans after treatment (Khan et al. 
1997, Black et al. 2006). Our patient had a normal bone min-
eral density scan 3 years after stopping alendronate therapy. 
Despite stopping alendronate for 5 years, she still developed 
bilateral femur shaft fractures within a year of starting iban-
dronic acid. This would suggest that the risk of an atypical 
femur fracture is increased by concurrent use of bisphospho-
Figure 3. Fractures of the left and right 
femurs.
Figure 2. Right femur at 3-month follow-up show-
ing a healing fracture (arrow).
Figure 4. After plate fixation.
nate rather than being due to accumulation of bisphosphonate 
in the bones from previous use. In beagles, the effect of sup-
pressed bone turnover by bisphosphonates has been reported 
to include increased bone strength, but with accumulation of 
microdamage and a reduction in energy absorption capacity 
and toughness (Mashiba et al. 2001). Microdamage accumula-
tion has been proposed to contribute to the fragility of osteo-
porotic bone (Burr et al. 1997). Such microdamage has been 
suggested to act as a stimulus for targeted bone remodeling 
through death of osteocytes, resulting in a further increase in 
microdamage; this gives rise to stress fractures such as our 
patient’s atypical femur fractures (Heino et al. 2009). 
KLP participated in the management of the patient and wrote the first draft. 
MHT reviewed the manuscript and was the attending surgeon for the patient.
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